Dermabrasion in Mississauga Canada
This method uses mechanical scraping in order to make the skin smoother by removing the superficial layers. Modern techniques and special electrical devices are used today. These can smoothen the skin scars which were caused by accidents, burns and acne. The aim of this technique is to smoothen the skin to a homogenous appearance which eliminates the height differences causes by sunken and protruding scars. As in chemical peeling, dermabration also removes the outer layers. The difference is that while peeling is being spread all over the surface, dermabration is applied to specific areas therefore better control on the depth of penetration is achieved.
Scars resulting from acne usually create small (2-3mm) craters. They usually appear on oily skin, which reacts poorly to chemical peeling, therefore, dermabration is the treatment of choice.
This method is not suitable for all parts of the body. It is usually used for treating the face, however, not every part of the face can be scraped, for example: the eyelids have a very thin and delicate skin that cannot be dermabrated.
Dermabration cannot make the scars completely disappear, it only blurs them and makes them look similar to the surrounding surface. If the scar is protruding, that would make it look more flat. If the scar is sunken, that would make the surface around look more flat.
The procedure takes from a few minutes up to 90 minutes, depending on the area involved. People from all age groups may be candidates for this procedure.
The healing process depends on patient's age, skin color and type, as well as other medical conditions. The surgeon uses a device called a dermatome which has an electric blaze that moves very fast while removing the outer skin layers.
Every procedure has its risks. The most common phenomenon is pigmentation changes, either to brighter or to darker color. Others include scar creation, usually caused by over-scraping (therefore many surgeons prefer to repeat the treatment several times). Tiny white spots can appear on your skin. It usually disappears, either by themselves or by using a sponge. Infection may also be possible.
After the treatment your skin will be reddish and swollen. That will disappear within a few days. It takes some time to see the final results. The most important thing is to avoid sun exposure, chlorinated water and any activity which may harm the area. Take the necessary precausions according to your surgeon's instructions.
More Mississauga info...
Mississauga Get around
Mississauga Transit [3]
Toronto Transit Commision (TTC) [4] (services some of the east end of the city near the Toronto boundary)
Oakville Transit [5] (services some of the west end of the city near the Oakville boundary)
Blue & White Taxi
Golden City Taxi
-
Mississauga Eat
Axia Restaurant and Bar, 5045 Plantation Place (Along Eglinton Ave W near Erin Mills), tel: 905-6082942. [7]. In the community of Erin Mills. A nicely designed ambient place with fully authentic Asian food being produced from separate kitchens. Specializes in Chinese, Japanese, Thai and Korean cuisine. Mains $15-20, appetizers $5-10. Fully liquor licensed with unique flavoured Korean soju and alchoholic bubble tea. A must for any Asian food lover and enough variety to last countless visits.
Hooks Grille, 26 Lakeshore Road East, tel: 905-2787665. Overlooking Port Credit harbour. Small intimate place with great cajun food. Mains $15-20, tapas $5-10. The tapas are big, order at most two. Beer lovers will want to try the local Old Credit ale on draft. -
Plastic Surgery News...
Context Individuals with diabetes are at increased risk for cardiovascular disease (CVD), but more aggressive targets for risk factor control have not been tested.
Objective To compare progression of subclinical atherosclerosis in adults with type 2 diabetes treated to reach aggressive targets of low-density lipoprotein cholesterol (LDL-C) of 70 mg/dL or lower and systolic blood pressure (SBP) of 115 mm Hg or lower vs standard targets of LDL-C of 100 mg/dL or lower and SBP of 130 mm Hg or lower.
Design, Setting, and Participants A randomized, open-label, blinded-to-end point, 3-year trial from April 2003-July 2007 at 4 clinical centers in Oklahoma, Arizona, and South Dakota. Participants were 499 American Indian men and women aged 40 years or older with type 2 diabetes and no prior CVD events.
Interventions Participants were randomized to aggressive (n=252) vs standard (n=247) treatment groups with stepped treatment algorithms defined for both.
Main Outcome Measures Primary end point was progression of atherosclerosis measured by common carotid artery intimal medial thickness (IMT). Secondary end points were other carotid and cardiac ultrasonographic measures and clinical events.
Results Mean target LDL-C and SBP levels for both groups were reached and maintained. Mean (95% confidence interval) levels for LDL-C in the last 12 months were 72 (69-75) and 104 (101-106) mg/dL and SBP levels were 117 (115-118) and 129 (128-130) mm Hg in the aggressive vs standard groups, respectively. Compared with baseline, IMT regressed in the aggressive group and progressed in the standard group (–0.012 mm vs 0.038 mm; P < .001); carotid arterial cross-sectional area also regressed (–0.02 mm2 vs 1.05 mm2; P < .001); and there was greater decrease in left ventricular mass index (–2.4 g/m2.7 vs –1.2 g/m2.7; P = .03) in the aggressive group. Rates of adverse events (38.5% and 26.7%; P = .005) and serious adverse events (n = 4 vs 1; P = .18) related to blood pressure medications were higher in the aggressive group. Clinical CVD events (1.6/100 and 1.5/100 person-years; P = .87) did not differ significantly between groups.
Conclusions Reducing LDL-C and SBP to lower targets resulted in regression of carotid IMT and greater decrease in left ventricular mass in individuals with type 2 diabetes. Clinical events were lower than expected and did not differ significantly between groups. Further follow-up is needed to determine whether these improvements will result in lower long-term CVD event rates and costs and favorable risk-benefit outcomes.
Trial Registration clinicaltrials.gov Identifier: NCT00047424
- La Jolla Pharmaceutical Company (Nasdaq:LJPC) announced significant progress in its ongoing double-blind, placebo-controlled randomized Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"), including additional safety data on the trial's higher doses.